Full Text View
Tabular View
No Study Results Posted
Related Studies
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
This study has been completed.
Study NCT00146835   Information provided by GlaxoSmithKline

First Received on September 6, 2005.   Last Updated on May 2, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Diphtheria
Hepatitis
Hepatitis A
Hepatitis B
Tetanus
Whooping Cough
More general conditions related to this trial
Actinomycetales Infections
Bacterial Infections
Bordetella Infections
Clostridium Infections
Corynebacterium Infections
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Gram-Negative Bacterial Infections
Gram-Positive Bacterial Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Infection
Liver Diseases
Picornaviridae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Pediarix
Licensed DTPa containing vaccine
Prevnar®: (Wyeth)
Sponsors listed in this trial
GlaxoSmithKline
Kaiser Permanente
University of California, Los Angeles


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services